Cargando…

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies

Cholestasis is a common clinical disease caused by a disorder in bile acids (BAs) homeostasis, which promotes its development. The Farnesoid X receptor (FXR) plays a critical role in regulating BAs homeostasis, making it an essential target for cholestasis treatment. Although several active FXR agon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xi, Lili, Shi, Axi, Shen, Tiantian, Wang, Guoxu, Wei, Yuhui, Guo, Jingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309033/ https://www.ncbi.nlm.nih.gov/pubmed/37397498 http://dx.doi.org/10.3389/fphar.2023.1197856

Ejemplares similares

Alterations in the gut microbiota and serum metabolomics of spontaneous cholestasis caused by loss of FXR signal in mice
por: Wei, Shizhang, et al.
Publicado: (2023)

Polygoni Multiflori Radix interferes with bile acid metabolism homeostasis by inhibiting Fxr transcription, leading to cholestasis
por: Dai, Yihang, et al.
Publicado: (2023)

Emodin Rescues Intrahepatic Cholestasis via Stimulating FXR/BSEP Pathway in Promoting the Canalicular Export of Accumulated Bile
por: Xiong, Xiao-Li, et al.
Publicado: (2019)

Roseburia intestinalis relieves intrahepatic cholestasis of pregnancy through bile acid/FXR-FGF15 in rats
por: Sun, Hanxiang, et al.
Publicado: (2023)

Ginsenoside Rc, as an FXR activator, alleviates acetaminophen-induced hepatotoxicity via relieving inflammation and oxidative stress
por: Zhong, Yadi, et al.
Publicado: (2022)

Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis
por: Ghosh, Swati, et al.
Publicado: (2023)

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
por: Sepe, Valentina, et al.
Publicado: (2016)

The zhuyu pill relieves rat cholestasis by regulating the mRNA expression of lipid and bile metabolism associated genes
por: Han, Jun, et al.
Publicado: (2023)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells
por: Stefela, Alzbeta, et al.
Publicado: (2021)

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
por: Diao, Yanyan, et al.
Publicado: (2018)

Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders
por: Appelman, Monique D., et al.
Publicado: (2021)

BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination
por: Jung, Hyunkyung, et al.
Publicado: (2020)

Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid
por: Lin, Huan, et al.
Publicado: (2019)

Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation
por: Schuster, Daniela, et al.
Publicado: (2011)

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Miyata, Sachiho, et al.
Publicado: (2021)

Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation
por: Yang, Fan, et al.
Publicado: (2016)

Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
por: Renga, Barbara, et al.
Publicado: (2012)

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
por: Wang, Yunjie, et al.
Publicado: (2023)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
por: Gomez-Ospina, Natalia, et al.
Publicado: (2016)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
por: Festa, Carmen, et al.
Publicado: (2017)

Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation
por: Wang, Yuting, et al.
Publicado: (2022)

Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling
por: Xiao, Yongtao, et al.
Publicado: (2018)

Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum
por: Grienke, Ulrike, et al.
Publicado: (2011)

DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials
por: Keshavarzi Arshadi, Arash, et al.
Publicado: (2020)

Involvement of oxidative species in cyclosporine-mediated cholestasis
por: Nsengimana, Bernard, et al.
Publicado: (2022)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats
por: Yang, Jing, et al.
Publicado: (2017)

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
por: Yan, Meng, et al.
Publicado: (2022)

Metabolomic Analysis Reveals the Therapeutic Effects of MBT1805, a Novel Pan-Peroxisome Proliferator-Activated Receptor Agonist, on α-Naphthylisothiocyanate-Induced Cholestasis in Mice
por: Wang, Chang, et al.
Publicado: (2021)

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists
por: Wang, Lingyan, et al.
Publicado: (2018)

Discovery of New Potent anti-MERS CoV Fusion Inhibitors
por: Kandeel, Mahmoud, et al.
Publicado: (2021)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021)

The Pathological Mechanisms of Estrogen-Induced Cholestasis: Current Perspectives
por: Zu, Yue, et al.
Publicado: (2021)

PPARα: A potential therapeutic target of cholestasis
por: Ye, Xiaoyin, et al.
Publicado: (2022)

Correction: Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling
por: Xiao, Yongtao, et al.
Publicado: (2022)

Assessing the Selectivity of FXR, LXRs, CAR, and RORγ Pharmaceutical Ligands With Reporter Cell Lines
por: Toporova, Lucia, et al.
Publicado: (2020)

Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling
por: Li, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_meqctupv19tk23nqt0dd1fl2mq